PFE - Pfizer Inc.
| Previous Close | 43.26 |
| Open | 43.37 |
| Bid | 43.45 x 2900 |
| Ask | 43.46 x 4000 |
| Day's Range | 43.34 - 43.58 |
| 52 Week Range | 33.20 - 43.68 |
| Volume | 2,646,972 |
| Avg. Volume | 19,674,784 |
| Market Cap | 255.354B |
| Beta | 0.87 |
| PE Ratio (TTM) | 11.63 |
| EPS (TTM) | 3.74 |
| Earnings Date | Oct 30, 2018 |
| Forward Dividend & Yield | 1.36 (3.17%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | 42.37 |
- Market Realist•10 minutes ago
Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
- Business Wire•3 hours ago
Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Pfizer Inc. (PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.
- The Wall Street Journal•5 hours ago
[$$] Companies' Brexit Challenge: Preparing for the Unknown
LONDON—Some of the world’s biggest companies are drawing up plans for the unplannable: a March divorce between Britain and the European Union, in which even some basic parameters have yet to be hammered out. PLC are stockpiling medicine, on orders from the British government, just in case of long delays at the border. It said that will better protect it from any supply-chain disruptions that might stem from a disorderly breakup.
- ACCESSWIRE•yesterday
Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Pfizer
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
- Market Realist•yesterday
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- MarketWatch•2 days ago
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
- Business Wire•2 days ago
New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
—Findings from sensitivity and post-hoc analyses were presented during a Late Breaking Clinical Trials Session at the Heart Failure Society of America 22nd Annual Scientific Meetin
- Market Realist•2 days ago
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Market Realist•2 days agoWatson Health Still the Key Driver for IBM’s AI Business
The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.
- Business Wire•2 days ago
Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 30, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
- Market Realist•2 days ago
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•2 days ago
Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.
- Zacks•2 days ago
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
- Market Realist•2 days ago
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Market Realist•2 days agoDelstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
- InvestorPlace•2 days ago
Cronos Gets Bigger As It Partners With Ginkgo Bioworks
From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.
- Zacks•3 days ago
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
- Market Realist•3 days ago
A Look at the Market Caps of the Pharma Stocks under Review
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
- Market Realist•3 days ago
How Pharmaceutical ETFs Have Performed in 2018
Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.
- Market Realist•3 days ago
These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.
- American City Business Journals•3 days ago
This cancer-fighting biotech sped from startup to IPO filing in 10 months
The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.
- Market Realist•3 days ago
Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.
- Business Wire•5 days ago
Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with profound psychological consequences. Both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 (33.6 points and 49.5 points for JAK3 and TYK2/JAK1, respectively) as measured by the Severity of Alopecia Tool (SALT) score (100 point scale).
- Market Realist•6 days ago
Wall Street Analysts Are Mostly Positive on Merck in September
Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.
- Zacks•6 days ago
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.
